### **Overview** Windlas Biotech Limited (WBL) is one of India’s leading contract development and manufacturing organizations (CDMOs) in the generic pharmaceuticals space. With over two decades of experience, the company operates across three core strategic business verticals (SBVs): 1. **Generic Formulations CDMO** – delivering end-to-end product development and commercial manufacturing services, 2. **Trade Generics & Institutional Sales** – marketing affordable, high-quality generic medicines under its own brands, and 3. **Exports** – targeting semi-regulated and regulated international markets. WBL has carved a differentiated position in the fragmented Indian pharma landscape through **in-house R&D**, **strong IP ownership**, **vertical integration**, and **GMP-compliant manufacturing excellence**. The company is listed on Indian stock exchanges (since August 2021) and is recognized for its focus on **complex, high-margin generics**, **operational agility**, and **strategic infrastructure investments**. --- ### **Key Business Verticals** #### **1. Generic Formulations CDMO (74% of H1FY26 Revenue)** - **Core Offering:** End-to-end CDMO services including product discovery, formulation development, regulatory filing, and commercial-scale manufacturing of solid, liquid, and injectable dosage forms. - **Key Clients:** Services provided to **7 of the top 10** and **16 of the top 20 Indian pharmaceutical companies**, including marquee names such as Zydus, Emcure, and Eris Lifesciences. - **Growth Momentum:** - 18% YoY revenue growth in H1FY26 - ₹5,551 million FY25 revenue (15% YoY growth) - Over **5,582 products** developed and **757 CDMO customers** served as of Jul–Nov 2025 - **IP Leadership:** Owns **99–100% IP rights** across the CDMO product lifecycle — from development to regulatory approvals — enabling higher EBITDA margins and reducing exposure to low-margin job-work models. - **Specialized Expertise:** Focus on high-value **complex generics** such as: - Fixed-dose combinations (FDCs) - Modified-release & sustained-release formulations - Chewable, dispersible, and flavored tablets - Medicated chewing gums - **Recent Expansion:** Commissioned a state-of-the-art **injectables facility** (producing **ampoules, liquid vials, lyophilized vials**) in Dehradun. This facility supports entry into **critical care, sterile, and specialized therapy markets** and is expected to contribute meaningful revenue from FY26 onward. #### **2. Trade Generics & Institutional (22% of H1FY26 Revenue)** - **Core Offering:** Own-branded, affordable generic medicines distributed **without medical representatives**, targeting underserved rural and semi-urban populations. - **Distribution Model:** Direct-to-stockist network across **all 29 Indian states** via **1,095 stockists and distributors**, enabling deep rural penetration (serving ~650,000 villages). - **AAA Strategy:** Anchored on **Accessibility, Affordability, and Authenticity**, leveraging **umbrella branding** to build trust and recognition. - **Key Therapeutic Areas:** - Anti-diabetic, cardiovascular, respiratory, gastroenterology, and multivitamins - Focuses on 59% chronic and sub-chronic conditions - **Growth Trajectory:** - Fastest-growing vertical over the last 3 years - 25% YoY growth in H1FY26; 74% YoY in Q3FY25 - Revenue of ₹1,721 million in FY25 (41% YoY growth), up from ₹1,224 million in FY24 - Brand portfolio expanded from **278 (FY23)** to **400 (FY25 forecast)** - **Government Synergy:** Strong participation in **Jan Aushadhi Yojana**, **Ayushman Bharat**, and state-level tenders, positioning to benefit from India’s target of **25,000 Jan Aushadhi stores** by 2026. #### **3. Exports (4–5% of Revenue)** - **Market Focus:** Semi-regulated and emerging markets across **10 countries**, including Southeast Asia, Africa, and the Middle East. - **Product Portfolio:** 69–80 SKUs exported, including **generic medicines and nutraceuticals**, under both **customer and in-house brands**. - **Growth & Strategy:** - Export revenue of **₹326 million in FY25 (19% YoY growth)** - Signed agreements to acquire **European marketing authorizations** to enter regulated markets - Active regulatory dossier filings in new geographies to accelerate market entry - Plans to grow exports into **>10% of revenue** over the long term - **Challenges:** Long gestation period for regulatory approvals and market acceptance. --- ### **Manufacturing & Infrastructure** - **Five State-of-the-Art Facilities:** All located in **Dehradun**, compliant with **WHO-GMP**, **Schedule M**, and audited by **EU-GMP** and **SAHPRA (South Africa)** authorities. - **Total Capacity (Annual):** - 8,522 million tablets and capsules - 54 million pouches/sachets - 61 million liquid bottles - **Recent Additions:** - **Plant-6 (Oral Solids):** Acquired and undergoing retrofitting to expand solid dosage capacity - **Injectables Facility (Plant-5):** Commissioned in FY24, now **GMP-certified (Uttarakhand FDA, Jan 2025)** with automated systems and real-time analytics - **Plant-2 Extension:** Added to diversify into **chronic and critical care therapies** - **Flexible Manufacturing:** Fungible infrastructure allows shift between CDMO, Trade Generics, and Exports based on market demand and profitability. - **Digital Transformation:** Implementing **Digital Quality Management System (QMS)** with real-time analytics to improve compliance, reduce cycle times, and enhance quality control. --- ### **R&D & Innovation** - **DSIR-Approved R&D Lab:** Equipped with **pilot-scale equipment** and supported by **177 dedicated QC personnel**. - **R&D Focus Areas:** - **First-to-market complex generics** (e.g., FDCs, modified-release therapies) - **Novel dosage forms:** dispersible tablets, chewable tablets, medicated gums - **High-bioavailability formulations & low-solubility drugs** - Targeting **upcoming patent expiries** (e.g., diabetes, cardio, urology) to accelerate time-to-market - **Product Pipeline:** - Licensed to manufacture **6,849 products** - 3,190 complex generics in pipeline - Over **5,582 CDMO products** commercially available - **R&D Investment:** - Consistent spend of ~**1.7–2% of revenue** (₹79 million in FY23) - Strong track record of securing **DCGI No Objection Certificates (NOC)** – 11 secured in FY24 alone --- ### **Financial Performance & Strategy** - **Revenue Breakdown (H1FY26):** - **CDMO:** 74% - **Trade Generics & Institutional:** 22% - **Exports:** 4% - **Revenue Growth (FY25):** - Total: **₹6,300+ million** - CDMO: **₹5,551 million (15% YoY)** - Trade Generics: **₹1,721 million (41% YoY)** - Exports: **₹326 million (19% YoY)** - **Profitability & Margins:** - Maintained **10–12% EBITDA margins** despite fixed costs from new injectables facility - Driven by **IP ownership**, **complex generics mix (67%)**, and **cost-efficient vertical integration** - **Liquidity & Cash Flow:** - **₹56 crores operating cash flow in H1FY26** - **₹237 crores in liquidity** – supports CAPEX, R&D, and inorganic growth opportunities - **CAPEX Plan (FY25–27):** - **₹50 crore** invested in injectables facility - **₹15–20 crore** for Plant-2 expansion - **₹30–35 crore** earmarked for future CAPEX toward **₹1,000 crore revenue target** --- ### **Market Positioning & Competitive Advantages** 1. **Vertical Integration & IP Ownership:** Fully in-house formulation development, pilot R&D, and full IP control create high entry barriers and margin protection. 2. **Quality & Compliance Leadership:** All five plants are **WHO-GMP and Schedule M certified**. Passed **70+ customer audits/year** including multinationals. Serves only **creditworthy, compliant clients**, reducing regulatory and credit risk. 3. **Diversified Revenue Model:** - CDMO for scale and stability - Trade Generics for high-margin domestic growth - Exports for future international expansion 4. **Reduced Client Concentration:** - Top 10 customers: **37% of CDMO sales in 9MFY25 (down from 47% in FY24)** - Largest client contributes <10% of total revenue 5. **Strategic Agility:** Flexible infrastructure enables rapid response to market shifts and capacity bottlenecks. --- ### **Growth Strategy** - **Short-Term (FY25–26):** - Ramp up injectables facility; target **₹60–70 crore run-rate** once stability testing and commercial validation complete - Expand **wallet share with existing CDMO clients** and acquire new ones - Grow Trade Generics brand count to 400+ and deepen rural penetration - **Medium-Term:** - Scale Exports via inorganic opportunities (brand/portfolio acquisitions) - Expand into new dosage forms: **gels, soft gels, ointments, eye drops** - Pursue **inorganic growth** (brownfield acquisitions) to accelerate scale - **Long-Term Vision:** - Become a **₹1,000 crores revenue company** - Triple Trade Generics revenue (~₹2,000 crores) and grow exports 4x - Maintain leadership as a **top-five domestic CDMO player** --- ### **Management & Governance** - **Leadership Team:** - **Mr. Ashok Kumar Windlass (Whole-time Director, Co-founder):** 55+ years’ experience in pharma manufacturing - **Mr. Manoj Kumar Windlass (Joint Managing Director):** 18+ years; leads product strategy, business development, and supply chain - **Key Appointments:** Mr. Shailendra Rastogi (Chief Business Officer, Dec 2021) to drive commercial expansion in CDMO and Exports. ---